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with no or mild pain during the follow-up period was obtained by
pregabalin (59.6%;CI95% 59.0%–60.2%); followed by gabap-
entin (49.2%; CI95% 48.7%–49.7%); amitriptyline (47.6%;
CI95% 47.1%–48.1%) and carbamazepine (34.4%; CI95%
34.1%–34.8%). The annual expected mean costs per patient
were US$3001.4 (CI95% US$2956.4–US$3046.3); US$4,707.7
(CI95% US$4689.9–US$4723.6); US$2814.4 (CI95%
US$2783.4–US$2845.5) and US$3701.9 (CI95% US$3687.2–
US$3716.6); respectively following the order above. The ICER’s
of pregabalin vs. carbamazepine (baseline), gabapentin and
amitriptyline were -US$700.5 (CI95% -US$670.4:-US$730.7),
-US$1706.4 (CI95% -US$1677.3:-US$1733.4) and US$186.9
(CI95% US$173.1–US$200.8); respectively. Using acceptability
curves (WTP US$5000–US$50,000), pregabalin showed a prob-
ability between 90–99% to be the treatment most cost-effective.
CONCLUSION: In Mexico, pregabalin showed to be a cost-
saving therapy when is compared with carbamazepine and gaba-
pentin; and cost-effective vs. amitriptyline in the management of
neuropathic pain.
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OBJECTIVE: The primary aim of type 2 diabetes (T2D) therapy
is helping patients achieve glycemic goals (A1C < 7%) as recom-
mended by the ADA. In the recent randomized controlled trials
4-T and INITIATE, patients treated with basal insulin alone
achieved goal 28% and 40% of the time, respectively, despite
progressive insulin titration. In this retrospective cohort study
using a large, US commercial health plan claims database, we
describe the clinical effectiveness of newly-prescribed basal
insulin glargine (IG) in insulin-naive patients. METHODS: A
total of 13,154 insulin-naïve (not prescribed insulin in previous
6 mo) patients were identiﬁed with a new prescription claim for
IG between January 1, 2004 and June 30, 2006, 6 mo of
pre-index eligibility (ﬁrst claim = index date), 12 mo of post-
index eligibility, and 18 y old. RESULTS: From this cohort,
7730 (59%) patients had no other insulin claims other than IG in
the entire post-index period. All patients with baseline (100 d
pre-index) and post-index (60–365 d) A1C data available and
baseline A1C7.0% were analyzed (n = 313; mean baseline A1C
(SD) = 9.8  2.1%). Mean (SD) age was 52  8 y (41%
female; 3%65 y). In this cohort of patients who did not add
any additional insulin (n = 313), 27% achieved A1C < 7% in the
post-index period (mean [min,max] time index to post-index
A1C = 238 d [63,365]). Mean (SD) post-index A1C was
8.2  1.9%. CONCLUSION: In this real-world analysis of
patients initiated on IG, the percentage of patients achieving
A1C < 7.0% and mean post-index A1C indicate that most
patients do not achieve recommended glycemic targets—results
which mirror controlled clinical studies. In addition, more than
half of patients initiating IG did not supplement with additional
insulin therapy over the course of the ﬁrst year of therapy, despite
not reaching glycemic goals. Because the contribution of post-
prandial glucose to A1C increases as A1C approaches goal,
agents targeting fasting glucose alone, like IG, may be insufﬁcient
in helping patients with T2D achieve glycemic goals.
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OBJECTIVE: The American Diabetes Association (ADA) recom-
mends metformin as ﬁrst line treatment for T2DM. As diabetes is
a progressive disease, patients will ultimately need additional
therapies to reach glycemic goals. Little information has been
published that describes what happens to patients not optimally
controlled on metformin monotherapy in the real world. We
analyzed monitoring, treatments and outcomes for such patients
using the PHARMetrics® linked laboratory database.
METHODS: An algorithm based on ICD-9 codes and laboratory
test values identiﬁed 1901 T2DM patients who failed metformin
monotherapy between 2000 and 2006. The index date was
deﬁned as the ﬁrst Hba1c test greater than the ADA recom-
mended goal of 7%, after at least 6 months metformin mono-
therapy. The pre-period was deﬁned as two years prior to the
index date. The follow-up period was deﬁned as 12 months after
the index date. Other laboratory test values were obtained during
a +/-30-day window of the index date. Micro- and macro-
vascular diabetes-related complications were identiﬁed using
ICD-9 codes during the pre-period. Subsequent glucose control
and ﬁrst therapy change in the 3 to 12 months of the follow-up
period were also analyzed. RESULTS: A total of 48.5% of the
sample was male. Mean age was 57.9 (11). The prevalence of
diabetic-related complications were as follows: retinopathy
(12.64%); neuropathy (12.13%); nephropathy (2.67%); myo-
cardial infarction (1.31%); stroke (2.82%) and ischemic heart
disease (12.99%). In the follow-up period, 76.5% of patients had
an Hba1c test and only 24.7% were at goal. Only 33% changed
therapy: 19% added on sulfonylurea; 5% switched to a ﬁxed-
dose combination product and 4% added or switched to thiazo-
lidinedione. Overall, the average time from failure until therapy
change was 256.0 days (73.1). CONCLUSION: These results
indicate considerable unmet medical need in treating T2DM.
Glycemic control would have likely been better with additional
pharmaceutical utilization.
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OBJECTIVE: To assess age, racial, and regional differences in
utilization of physician, hospital outpatient and emergency
department services related to stroke over the past six years.
METHODS: This study was a retrospective analysis of the
National Ambulatory Medical Care Survey (NAMCS) and the
National Hospital Ambulatory Medical Care Survey (NHAMCS)
from 2000..C2005. Ischemic stroke related visits in persons aged
45 years were identiﬁed using diagnosis codes (ICD 9 CM)
433.1x, 434.xx, and 436.xx. Visits per/1000 persons were calcu-
lated using United States population estimates. With logistic
regression, we adjusted associations between stroke-related visits
and age, race, and region (Northeast, Midwest, West, and South),
for sex, stroke risk factors, insurance type, and survey year.
RESULTS: From 2000 to 2005, stroke-related ambulatory care
visits increased signiﬁcantly from 8.3/1000 persons to 16.1/1000
persons (P Trend=<0.0001)..Crepresenting a 195% rise in stroke
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